Chemokine receptors and signaling

This study confirms that CXCL17 activates MRGPRX2, MRGPRX1, and MAS1 independently of its C-terminal fragment, unlike its effect on GPR25.

The paper shows that chemokine receptors in macrophages are non-redundant and change with differentiation and inflammatory stimuli.

This study characterizes VUF16840 as a selective inverse agonist of ACKR3 that inhibits constitutive and chemokine-induced signaling by stabilizing the inactive conformation of the receptor.

This study identifies CXCL5 as a factor that increases alveolar-epithelial barrier permeability in acute lung injury, independent of neutrophil recruitment.

This study identifies the CXCL10/CXCR3 axis as critical for maintaining immunological dormancy in breast cancer and shows its potential as a therapeutic target and prognostic marker in TNBC.

This study identifies N-terminal determinants of CCL27 and CCL28 receptor activation and selectivity by analyzing mutations and using AlphaFold models.

This study shows human CXCL17 activates and binds to fish GPR25 orthologs, suggesting conservation of the CXCL17-GPR25 interaction across vertebrates.

This study identifies a non-canonical activation mechanism of CCR9 by CCL25 through structural modeling and mutational analysis, revealing the 30s loop as the key activation region.

This study shows that CXCL12-LD, a dimeric variant of the chemokine, reduces chemotaxis in AML cells by altering receptor signaling and internalization, suggesting potential for improved CXCR4 targeting.

The paper demonstrates a synthetic dual-moiety strategy to design CXCR4 agonist peptides that mimic SDF-1, showing therapeutic benefit in a mouse model of ALS through neuroprotection.

This study identifies C/EBPβ as a key driver of colitis-associated tumorigenesis by promoting neutrophil infiltration via the CXCL1/CXCL2/CXCL5-CXCR2 axis, suggesting it as a therapeutic target.

This study shows that disrupting CXCR4 oligomers in lymphoid cancers reduces migration, survival signaling, and tumor growth, while sensitizing cells to venetoclax.

This study shows that crosslinked CXCR4 on T cells reduces their motility and increases adhesion through a non-Gi-dependent pathway involving PTK2B and integrin β4.

This study shows that CCR1/2/3/5 deletion reduces CD4 T cell responses but not CD8 T cell responses to influenza virus infection.

This study investigates the dual role of the CXCL10-CXCR3 axis in osteosarcoma, showing it promotes tumor growth but also recruits immune cells, suggesting CXCR3 inhibition could target metastasis.

This study shows GPR15LG binds CXCR4, enhancing CXCL12-induced signaling and promoting cell migration in immune and cancer cells.

This study identifies GPR25 as the receptor for CXCL17 using AlphaFold 3 prediction and NanoBiT-based assays, showing specific activation and structural binding.

This study identifies a CXCL12/CXCR4/BMI1 signaling axis that promotes metastasis in PDAC via tumor-stroma crosstalk and shows that JM#21, a CXCR4 inhibitor, suppresses miCSCs and enhances chemotherapy efficacy.

This study develops a fluorescent ligand to identify improved antagonists targeting the intracellular allosteric site of CCR7, showing their effectiveness in both recombinant and endogenous settings.

This paper develops an ex vivo model of breast cancer cell invasion in live lymph node tissue, revealing preferential invasion patterns and immune-related resistance mechanisms.

The paper computationally optimizes a peptide inhibitor of the CXCL12/HMGB1 heterocomplex, resulting in a variant with significantly improved affinity and activity.

This study investigates how neutrophil-like HL-60 cells respond to traveling waves of chemoattractants, finding that cell movement depends on wave speed and involves different signaling pathways at the front and back of the wave.

The paper performs a meta-analysis of scRNA-seq data to identify disease-specific and shared chemokine-based cell communication patterns in immune diseases.

This study shows CXCL12 gradients around TMEM doorways promote tumor cell invasion and create immunosuppressive niches by affecting CD8+ T cell function and distribution.

This study examines the evolutionary diversity of the CXCL16-CXCR6 axis across vertebrates, identifying motif substitutions and recurrent gene loss in various species.

This paper shows that a CXCR4 partial agonist enhances immunotherapy in gastric cancer by targeting PMN-MDSCs and granulopoiesis.

This study shows that ACKR3 agonism promotes heterodimerization with CXCR4 in platelets, reducing platelet activation and thrombus formation by modulating CXCR4 signaling.

This study shows NMI promotes neutrophil recruitment by activating the NF-kappaB pathway and inducing chemokine release in murine models.

The paper investigates whether CCR8 is a high-affinity receptor for CCL18 and finds that CCR8 does not respond to CCL18 in multiple assays.

This study identifies GPR182/ACKR5 as a scavenger receptor for CXCL17, GPR15L, and endogenous peptides, revealing distinct binding modes and expanding its ligand repertoire beyond classical chemokines.